|Other Names||Alpha-1, 6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A, Alpha-mannoside beta-1, 6-N-acetylglucosaminyltransferase, GlcNAc-T V, GNT-V, Mannoside acetylglucosaminyltransferase 5, N-acetylglucosaminyl-transferase V, MGAT5, GGNT5|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13815b was selected from the C-term region of MGAT5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the addition of N-acetylglucosamine in beta 1- 6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides. It is one of the most important enzymes involved in the regulation of the biosynthesis of glycoprotein oligosaccharides.|
|Cellular Location||Golgi apparatus membrane; Single-pass type II membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes mannosyl (alpha-1,6-)-glycoproteinbeta-1,6-N-acetyl-glucosaminyltransferase, a glycosyltransferaseinvolved in the synthesis of protein-bound and lipid-boundoligosaccharides. Alterations of the oligosaccharides on cellsurface glycoproteins cause significant changes in the adhesive ormigratory behavior of a cell. Increase in the encoded protein'sactivity may correlate with the progression of invasivemalignancies.
Dick, D.M., et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (6), 1179-1188 (2010) :Brynedal, B., et al. J. Neuroimmunol. 220 (1-2), 120-124 (2010) :Benson, V., et al. Int. Immunol. 22(3):167-177(2010)Wang, C., et al. J. Cell. Biochem. 109(1):113-123(2010)Ding, H., et al. Stroke 41(1):177-180(2010)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.